SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Hope for new psoriasis treatment
Fri October 30th - A possible new therapy for psoriasis has shown promise, a European conference has heard. More
Shop workers' risk of getting COVID-19
Fri October 30th - Customer-facing shop staff are about five times more likely to test positive for COVID-19 than their colleagues in other positions, a small American study has found. More
CA125 test better at predicting ovarian cancer
Fri October 30th - A readily available blood test is able to predict ovarian cancer risk more successfully than previously thought – particularly for the over 50s, according to newly published findings. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

New drug option for heart disease prevention

Wednesday September 2nd 2020

The common gout medication, colchicine, may help prevent major cardiovascular events in patients with chronic coronary disease, a European conference has heard.

The drug inhibits several inflammatory pathways, including those relating to atherosclerosis.

It was tested by a team led by Dr Mark Nidorf of GenesisCare, a major heart disease treatment provider in Australia.

They gave 5,552 patients with coronary artery disease either 0.5mg colchicine per day, or placebo, for 30 days. All patients were also given lipid lowering and antithrombotic therapy.

After a follow up of about 30 months, the drug was found to be safe and effective for preventing cardiovascular events - that is, cardiovascular death, myocardial infarction, ischaemic stroke, or ischaemia-driven coronary revascularisation.

Such events were seen in 6.8% of patients on colchicine and 9.6% of patients on placebo. This represents a significant improvement.

When analysed further, reductions were seen in each of the endpoints in the colchicine group.

Side-effects were experienced by 10% of patients on colchicine and were mostly gastrointestinal. For those participants taking the drug over a longer duration, it did not cause any serious side-effects.

Findings were presented on Monday (31 August) at the at the European Society of Cardiology Congress 2020, held online.

Dr Nidorf said: “Over a decade, more than one in three heart patients will have another heart attack or stroke, or die from heart disease, despite taking preventive medication. Our study shows that this could be reduced to one in four with the addition of low-dose colchicine.

“The benefits were seen soon after initiating therapy, continued to accrue over time, and were observed patients already receiving other effective prevention therapies.”

Abstract title: Low-dose colchicine in patients with stable coronary artery disease. Presented at ESC Congress 2020 on Monday 31 August 2020

Tags: Australia | Europe | Gastroenterology | Heart Health | Pharmaceuticals

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES